Blog | Gen Re

Our Perspective

CEA Screening - Useful in Life & Health Underwriting?

By Dr. Thomas Ashley |March 26, 2020|English

Some insurers have added the carcinoembryonic antigen (CEA) blood test to the laboratory screening profile for Life and Health insurance applications, and some of our U.S. clients have asked for advice on whether to adopt this test. Every test has repercussions...
Read More
Insurance Idea Pulse 2020: Where Is Life and Health Insurance Making Innovations?

By Ewa Widenka, Ninety Consulting (guest contributor)|March 11, 2020|English

“There are only five ideas in insurance” is a throw away comment we overheard at a Ninety Consulting workshop, but it got us thinking: Is this a fair assessment of the state of insurance innovation today? We reviewed more than 500 innovations...
Read More
An International View of the Living to 100 Symposium - a Good Look at Mortality Risk

By Beata Puls |March 03, 2020|English

Even though the SOA’s Living to 100 Symposium takes place in the U.S. and the majority of attendees are from North America, I found it to be a huge benefit for international participants to attend. The 2020 Symposium did not disappoint. For me,...
Read More
5 Things I Learned at the SOA LT100 Symposium

By Jean-Marc Fix |February 27, 2020|English

At the Living to 100 Symposium, I enjoyed the Orlando, Florida January weather but, more importantly, the fellowship that makes this symposium extra special for everyone, not just for actuaries. Now the organizing committee is busy reading reviews and...
Read More
Group Medical EOI - U.S. Benchmarking Survey Identifies Underwriting Challenges

By Joe Iannetti |February 11, 2020|English

In the fourth quarter of 2019, Gen Re released the results of our Group Medical Evidence of Insurability Underwriting Survey. The survey focused on how companies staff for and process their Evidence of Insurability (EOI) applications; it included Group...
Read More
Understanding Viral Hepatitis - What’s Relevant to Underwriting?

By Dr. Sandra Mitic and Annika Tiedemann |January 23, 2020|English

Prevalence, current therapies and prevention are the key themes for insurers that are reviewing their approach to applications with a history of viral hepatitis. As its name suggests, viral hepatitis is the term used to describe diffuse inflammation...
Read More